Lly stock forecast the LLY stock forecast remains

The LLY stock forecast remains optimistic as Q2 2024 earnings beat estimates by 6%. Eli Lilly’s gross margin of 79% reflects excellent pricing power in patented drugs. Analysts view current pullbacks as healthy retracements within a broader bullish structure. In summary, investors dropped Novo Nordisk's stock for several reasons. (i) Fierce competition from pharma giant Eli Lilly expecially in the injectable form of compound since its recent phase 3 data showed inferior profile for the oral compound with around 12% weight-loss at week 72 vs. New! Get unlimited breaking news with a free Seeking Alpha account » Contemporary LLY stock forecast sentiment data from social finance forums reveals increased retail investor interest, often a precursor to heightened trading volume and short-term surges.